U.S. Markets closed

Stock Performance Review on ACADIA Pharma and Three Other Biotech Stocks

Stock Research Monitor: AKAO, ACHN, and ACOR

LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on ACAD sign up now at www.wallstequities.com/registration. On Thursday, the NASDAQ Composite ended the day at 7,442.12, down 0.27%; the Dow Jones Industrial Average edged 1.02% lower, to finish at 24,415.84; and the S&P 500 closed at 2,705.27, marginally slipping 0.69%. Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

ACADIA Pharmaceuticals

San Diego, California headquartered ACADIA Pharmaceuticals Inc.'s stock finished Thursday's session 0.06% lower at $18.10 with a total trading volume of 1.33 million shares. The stock has gained 9.83% in the past month. The Company's shares are trading below their 50-day moving average by 5.90%. Moreover, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 49.06. Get the full research report on ACAD for free by clicking below at:

www.wallstequities.com/registration/?symbol=ACAD

Achaogen

Shares in South San Francisco, California-based Achaogen Inc. rose 1.06%, ending yesterday's session at $12.40 with a total trading volume of 671,240 shares. The stock has gained 18.89% in the previous three months. The Company's shares are trading below their 50-day moving average by 0.86%. Moreover, shares of Achaogen, which focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant gram-negative infections in the US, have an RSI of 49.80. Gain free access to the research report on AKAO at:

www.wallstequities.com/registration/?symbol=AKAO

Achillion Pharmaceuticals

On Thursday, New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.'s stock saw a drop of 2.31%, to close the day at $3.39. A total volume of 985,626 shares was traded. The Company's shares have advanced 2.11% in the previous three months. The stock is trading below its 50-day moving average by 7.36%. Additionally, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the US, have an RSI of 39.29.

On May 21st, 2018, research firm Barclays upgraded the Company's stock rating from 'Underweight' to 'Equal Weight', with a target price of $5 per share. Register for your free report coverage on ACHN at:

www.wallstequities.com/registration/?symbol=ACHN

Acorda Therapeutics

Shares in Ardsley, New York headquartered Acorda Therapeutics Inc. ended the day 0.19% lower at $26.25. A total volume of 554,150 shares was traded, which was above their three months average volume of 413.29 thousand shares. The stock has gained 11.94% in the last month and 90.22% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 11.14% and 9.91%, respectively. Furthermore, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 72.46. Get the free research report on ACOR at:

www.wallstequities.com/registration/?symbol=ACOR

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities